Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DOR Biopharma’s orBec For GI Disease Misses Primary Endpoint

This article was originally published in The Pink Sheet Daily

Executive Summary

Company is relying on “volume of evidence” showing clinical benefit to win FDA approval.

You may also be interested in...



FDA Extends Review Of orBec For Acute GI Graft-Versus-Host Disease

DOR BioPharma, meanwhile, has launched a Phase II trial of the oral beclomethasone dipropionate product in the prophylactic GVHD setting.

FDA Extends Review Of orBec For Acute GI Graft-Versus-Host Disease

DOR BioPharma, meanwhile, has launched a Phase II trial of the oral beclomethasone dipropionate product in the prophylactic GVHD setting.

CTI Plans To File Pixantrone For Non-Hodgkin’s Lymphoma In Early 2008

First pixantrone NHL filing likely will be in the “aggressive/salvage setting,” CEO tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel